The BTG3 Knockout HEK293T Polyclonal Cells constitute a polyclonal knockout cell population derived from the widely utilized HEK293T human embryonic kidney cell line, engineered via CRISPR/Cas9-mediated disruption of the BTG3 gene. This product eliminates functional BTG3 protein expression, generating a loss-of-function model that enables systematic investigation of BTG3-dependent biological processes without the confounding effects of residual wild-type activity. The polyclonal format preserves the genetic heterogeneity of the edited pool, offering a robust resource for studying the collective cellular responses to BTG3 ablation in a high-throughput-compatible host.
The parental HEK293T cell line, a derivative of HEK293 cells, stably expresses the SV40 large T antigen, which facilitates episomal replication of transfected plasmids and enhances recombinant protein yield. These adherent epithelial cells are prized for their exceptional transfectability and are routinely employed for protein expression, viral packaging, and gene manipulation experiments. Their well-characterized growth properties and compatibility with standard cell culture techniques make them an ideal chassis for generating engineered knockout derivatives such as this BTG3-disrupted polyclonal population.
BTG3 is a critical tumor suppressor that mediates anti-proliferative signals through its association with the CCR4-NOT deadenylase complex, directly interacting with CNOT7 and CNOT8. Upon DNA damage, BTG3 is transcriptionally activated by p53 (TP53) and subsequently functions to inhibit E2F1 transcriptional activity and downregulate cyclin D1 (CCND1), thereby enforcing G1/S cell cycle arrest. Additionally, BTG3 contributes to the modulation of apoptosis and participates in the MAPK/ERK signaling cascade. This network positions BTG3 at the nexus of cell cycle checkpoints, DNA damage response, and growth factor signaling.
In the HEK293T background, disruption of BTG3 abrogates its growth-suppressive functions, creating a model system that mimics tumor cell phenotypes characterized by unchecked cell cycle progression and impaired DNA damage checkpoints. The polyclonal knockout cells circumvent clonal bias and are particularly suited for examining the average effects of BTG3 loss on proliferation dynamics, apoptotic thresholds, and gene expression programs. Given that HEK293T cells are inherently amenable to multiwell screening formats, this model is valuable for conducting parallel comparisons between wild-type and BTG3-null populations under various stress conditions, including genotoxic insults and chemotherapeutic challenges.
The BTG3 Knockout HEK293T Polyclonal Cells support a wide array of research applications including the dissection of cell cycle regulatory networks, mechanistic studies of tumor suppression, and high-content screening of anticancer agents. Representative assays include flow cytometry for cell cycle phase distribution, Annexin V-based apoptosis detection, MTT or CCK-8 proliferation measurements, E2F1 reporter assays to quantify transcriptional activity, and co-immunoprecipitation to validate protein?Cprotein interactions within the p53-BTG3-CCR4-NOT axis. Researchers can also combine this model with RT-qPCR and Western blotting to correlate transcript and protein changes with functional outcomes. For further information or to request custom formulations, please contact Ascent Research.
